NeuroScientific Biopharmaceuticals (ASX: NSB) Appoints Chris Knee as Chief Financial Officer

Aditi Sarkar

22 October 2026 06:44 PM AEDT

NeuroScientific Biopharmaceuticals (ASX: NSB) Appoints Chris Knee as Chief Financial Officer

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

NeuroScientific has appointed Mr Chris Knee as Chief Financial Officer.
He starts on Monday 26 October 2026.
Mr Knee is a Chartered Accountant with more than 20 years’ experience, mainly with ASX-listed companies.
The company is prioritising StemSmart™ for refractory Crohn’s disease and is planning Phase 2 clinical trials.

NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has appointed Mr Chris Knee as its Chief Financial Officer, effective Monday 26 October 2026. The Australian biotechnology company develops therapies for immune-mediated inflammatory diseases with large treatment-resistant populations.

Who Is Chris Knee

Mr Knee is a Chartered Accountant with more than 20 years’ experience in senior finance, executive, company secretary and director roles, predominantly with ASX-listed companies.

He has particular expertise in commercial contracts, including structuring and negotiating key agreements, complemented by a background in executive-level financial accounting, compliance and corporate governance.

About NeuroScientific and StemSmart

NeuroScientific focuses on therapeutics that modulate pathological immune responses involved in chronic and degenerative conditions, particularly where current options have limited efficacy or durability.

The company is prioritising its proprietary StemSmart™ technology for refractory Crohn’s disease, a severe and treatment-resistant form of the condition. StemSmart is derived from adult human donor bone marrow-sourced mesenchymal stem cells (MSCs) produced using a patented manufacturing process developed at Royal Perth Hospital in Western Australia.

What Comes Next

NeuroScientific is planning Phase 2 clinical trials to evaluate safety and preliminary efficacy in refractory and/or fistulising Crohn’s disease, with the goal of making the treatment available to patients for whom current therapies are inadequate.

The announcement does not disclose Mr Knee’s remuneration or any other terms of the appointment, and it does not provide trial dates or funding details.

Key Takeaways

NeuroScientific has added an experienced ASX finance executive as it prepares for Phase 2 trials of StemSmart in refractory Crohn’s disease. The announcement is a leadership update, and the company has not provided new clinical or financial information. This article is general information only and is not financial advice.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.